《港樓》嘉華國際(00173.HK) 英皇道項目命名爲「嘉居·天後」 提供74夥
嘉華國際(00173.HK)旗下英皇道33號項目正式命名爲「嘉居·天後」(KABITAT .TIN HAU)。嘉華國際營銷及市場策劃總經理(香港地產)朱美儀表示,項目提供74個單位,主打兩房及三房戶,並設有少量特色單位。
朱美儀指,現正積極部署「嘉居·天後」的銷售工作,期望項目可在第三季推售,而定價將會參考港島區豪宅項目。她透露,項目大部分單位料以價單形式推售。
她提到,「嘉居·天後」的關鍵日期爲2026年11月5日。另外,集團旗下醫院道項目期望可於今年內推出。
對於樓市,她表示,本港一二手市場活躍,預料樓市將價量齊升,加上經濟向好,相信之後買家會更積極入市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.